CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID‐19 therapy. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Machado, Thiago L.; Santos, Alanna C.; Azamor, Tamiris; da Silva, Andrea M. V.; Pimenta, Vanessa R.; Tubarão, Luciana N.; da Silva, Alexandre dos Santos; Flores Rodrigues, Daniela Del Rosário; Müller, Rodrigo; Pinto, Marcelo A.; Villar, Livia M.; Bom, Ana P. A.; Melgaço, Juliana G.
• Is Part Of: Journal of medical virology. Volume 95:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-31
• Subjects: CLEC5A -- COVID‐19 -- immunotherapy -- monocytes -- spike protein; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.28427
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: The immune response is crucial for coronavirus disease 19 (COVID‐19) progression, with the participation of proinflammatory cells and cytokines, inducing lung injury and loss of respiratory function. CLEC5A expression on monocytes can be triggered by viral and bacterial infections, leading to poor outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is able to induce neutrophil activation by CLEC5A and Toll‐like receptor 2, leading to an aggressive inflammatory cascade, but little is known about the molecular interactions between CLEC5A and SARS‐CoV‐2 proteins. Here, we aimed to explore how CLEC5A expression could be affected by SARS‐CoV‐2 infection using immunological tools with in vitro, in vivo, and in silico assays. The findings revealed that high levels of CLEC5A expression were found in monocytes from severe COVID‐19 patients in comparison with mild COVID‐19 and unexposed subjects, but not in vaccinated subjects who developed mild COVID‐19. In hamsters, we detected CLEC5A gene expression during 3–15 days of Omicron strain viral challenge. Our results also showed that CLEC5A can interact with SARS‐CoV‐2, promoting inflammatory cytokine production, probably through an interaction with the receptor‐binding domain in the N‐acetylglucosamine binding site (NAG‐601). The high expression of CLEC5A and high levels of proinflammatory cytokine production were reduced in vitro by a human CLEC5A monoclonal antibody. Finally, CLEC5A was triggered by spike glycoprotein, suggesting its involvement in COVID‐19 progression; therapy with a monoclonal antibody could be a good strategy for COVID‐19 treatment, but vaccines are still the best option to avoid hospitalization/deaths.